RECRUITING

Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a prospective natural history study of CIPN in approximately 200 participants receiving taxanes (paclitaxel, docetaxel) for breast cancer, bortezomib for multiple myeloma, oxaliplatin-based regimens for colorectal cancer, or vincristine for lymphoma.. Demographic data, medical history, electronic PROs, ClinROs blood biomarkers including NF-L, PGx DNA analyses and Bedside-QST will be assessed at Baseline. The Observation Period will initiate with the first dose of chemotherapy and conclude with the last dose of chemotherapy. During the Observation Period, participants will be evaluated for the development of CIPN using PROs and ClinROs. Blood biomarkers and Bedside-QST will be measured at various timepoints corresponding with treatment regimen schedules throughout the observation period. The Post Chemotherapy Follow-up Period will begin with the first visit after the last dose of chemotherapy and conclude 6 months after the last dose of chemotherapy. During the Post Chemotherapy Follow-up Period, participants will be evaluated for CIPN using PROs and ClinROs. Blood biomarkers and Bedside-QST will also be measured at the beginning and at the end of the Post-Chemotherapy Follow-up Period. PROs will be assessed electronically on a monthly basis.

Official Title

Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)

Quick Facts

Study Start:2019-07-03
Study Completion:2024-04-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03997981

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age ≥18 years
  2. * Life expectancy ≥6 months
  3. * Participants with Common Terminology Criteria for Adverse Events (CTCAE) Grade 0 CIPN (exception, patients with multiple myeloma treated with bortezomib, CTCAE Grade \<=1)
  4. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  5. * Breast cancer only:
  6. * Breast cancer beginning treatment with paclitaxel or docetaxel with curative intent (i.e., not metastatic disease beyond regional lymph nodes)
  7. * Planned minimum of 6 cycles of chemotherapy
  8. * Lymphoma only:
  9. * Incident lymphoma initiating treatment with vincristine
  10. * Planned minimum of 4 cycles of chemotherapy
  11. * Oxaliplatin-based regimens, Stage III colorectal cancer: Total of 6 months (planned minimum of 12 cycles). May consider Stage IV with minimal metastatic confirmed with Sponsor prior to enrollment
  12. * Bortezomib use in untreated multiple myeloma: Total of 4 months (planned minimum of 9 cycles)
  13. * Written informed consent given
  14. * Enrollment must be completed prior to receiving the first dose of chemotherapy
  1. * Evidence of central nervous system metastases
  2. * Evidence of clinically significant peripheral neuropathy (CTCAE \>2) as defined by patient report of frequent numbness or tingling in the hands or feet
  3. * Any uncontrolled serious illness or medical condition that would impact the conduct of the current study
  4. * Previous exposure to neurotoxic chemotherapy drugs
  5. * Pre-existing neurodegenerative disease (Parkinson's, Alzheimer's, Huntington's, etc.), neuromuscular disorder (multiple sclerosis, ALS, polio, hereditary neuromuscular disease) or history of stoke or history of traumatic brain injury
  6. * General anesthesia less than one month prior to the first dose of neurotoxic chemotherapy

Contacts and Locations

Study Contact

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
CONTACT
1-317-615-4559
ClinicalTrials.gov@lilly.com

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
STUDY_DIRECTOR
Eli Lilly and Company

Study Locations (Sites)

Alpha Oncology Research LLC
DeBary, Florida, 32713
United States
University of Maryland School of Medicine
Baltimore, Maryland, 21201-1544
United States
Johns Hopkins University School of Medicine
Baltimore, Maryland, 21287
United States
University of Michigan
Ann Arbor, Michigan, 48109-0400
United States
Mayo Clinic
Rochester, Minnesota, 55905-0002
United States
Washington University Medical School
Saint Louis, Missouri, 63110
United States
Ohio State University
Columbus, Ohio, 43212
United States
University of Pensylvania Hospital
Philadelphia, Pennsylvania, 19104
United States
University of Vermont Medical Center
Burlington, Vermont, 05401
United States
VCU Medical Center
Richmond, Virginia, 23298
United States

Collaborators and Investigators

Sponsor: Disarm Therapeutics

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-07-03
Study Completion Date2024-04-09

Study Record Updates

Study Start Date2019-07-03
Study Completion Date2024-04-09

Terms related to this study

Keywords Provided by Researchers

  • CIPN

Additional Relevant MeSH Terms

  • Chemotherapy-induced Peripheral Neuropathy